Abstract
Hypothesis Coronavirus disease 2019 (COVID-19) resulted in a 30% mortality rate in thoracic cancer patients. Given that cancer patients were excluded from serum anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine registration trials, it is still unknown whether they would develop a protective anti-spike antibody response following vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to SARS-CoV2 vaccine in thoracic cancer patients.
Methods SARS-CoV2-spike antibodies were measured using Abbot ARCHITECT SARS-CoV-2 IgG immunoassay, prior to first injection of BNT162b2 mRNA vaccine, as well as at Week 4, and two-to-sixteen weeks after second vaccine dose. The factors associated with antibody response were analyzed.
Results Overall, 306 patients, with a median age of 67.0 years (IQR=58-74), were vaccinated. Of these, 283 patients received two vaccine doses at 28-day intervals. After 4.7-month median follow-up, seven patients (2.3%) contracted proven symptomatic SARS-CoV-2 infection, with rapid favorable evolution. Of 269 serological results available beyond Day 14 post-second vaccine dose, 17 (6.3%) were still negative (<50 AU/mL) (arbitrary units/mL), while 34 (11%) were <300 AU/mL (12.5th percentile). In multivariate analysis, only age and chronic corticosteroid treatment were significantly associated with a lack of immunization. Thirty patients received a third vaccine dose, with only three patients showing persistent negative serology thereafter, whereas the others demonstrated clear seroconversion.
Conclusion SARS-CoV2 vaccines were shown to be efficient in thoracic cancer patients, most of them being immunized after two doses. A third shot given to 1% of patients with persistent low antibody titers resulted in a 88% immunization rate.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04776005
Funding Statement
The Assistance Publique-Hopitaux de Paris funded the study, without participating to study design, data collection, data analysis, data interpretation, or report writing.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Comite d'Evaluation de l'Ethique des projets de Recherche Biomedicale (CEERB, IRB00006477) of University Hospitals Paris-North Val-de-Seine, Paris 7 University, Assistance Publique-Hopitaux de Paris (AP-HP) upon the approval number CER-2021-72
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authors contribution:conceptualization: GZ, VG, DD, LT; supervision: GZ, VG; data curation: GZ, CM, ZB, GS, VG, VMF; Formal analysis: GZ, GS, VG, EV, VMF; Funding acquisition: GZ, LT, HF, DD, EV; Investigation: GZ, VG, GS, SA, AB, CM, ZB; Biological analyses: VMF, CC, HF, NF, GC, DD; Statistical analyses: GS, EV; original draft: GZ; review & editing: GZ, VG, GS, VMF, HF DD, EV, EV; final MS approbation: all authors.
Conflict of interest statement: Valentine Marie Ferré, Ghassen Soussi, Charlotte Charpentier, Héloïse Flament, Nadhira Fidouh, Gilles Collin, Céline Namour, Sandra Assoun, Alexandra Bizot, Zohra Brouk, Eric Vicaut, Luis Teixeira have nothing to disclose.
Gérard Zalcman received research grants from Roche-France, BMS, Takeda outside of the submitted work, perceived fees from BMS, Astra-Zeneca, Pfizer, Borhinger-Ingelheim outside the submitted work and reimbursement for international meetings assistance from Abbvie, MSD, Astra-Zeneca, BMS, Roche-France;
Valérie Gounant reports personal fees from MSD, Chugai, Novartis, and Boehringer; personal fees and non-financial support from Astra Zeneca, BMS, Takeda, and Pfizer; grants, personal fees, and non-financial support from Roche, all outside the submitted work;
Diane Descamps reports fees from Viiv-healthcare, Gilead-Sciences, Janssen-Cilag outside the submitted work;
Data Availability
All the data are available on request to the senior authoor of the article, Prof. Gerard ZALCMAN gerard.zalcman{at}aphp.fr
